- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00004480
Study of Botulinum Toxin in Patients With Primary Hyperhidrosis
June 23, 2005 updated by: Icahn School of Medicine at Mount Sinai
OBJECTIVES:
I. Determine the optimal dose of botulinum toxin necessary to decrease sweating in patients with primary hyperhidrosis.
Study Overview
Detailed Description
PROTOCOL OUTLINE:
Patients receive injections of botulinum toxin in the clinical trial for 6 months. Patients undergo an iodine starch test and a sympathetic skin response test to assess the efficacy of the drug. Patients also complete questionnaires to evaluate the amount of sweating.
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Mount Sinai School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
- Diagnosis of hyperhidrosis
- Excessive sweating in the hands, feet, armpits, forehead, or body
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Horacio Kaufmann, Icahn School of Medicine at Mount Sinai
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 1999
Study Registration Dates
First Submitted
October 18, 1999
First Submitted That Met QC Criteria
October 18, 1999
First Posted (Estimate)
October 19, 1999
Study Record Updates
Last Update Posted (Estimate)
June 24, 2005
Last Update Submitted That Met QC Criteria
June 23, 2005
Last Verified
July 1, 2004
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Sweat Gland Diseases
- Skin Diseases
- Hyperhidrosis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins
- Botulinum Toxins, Type A
- abobotulinumtoxinA
Other Study ID Numbers
- 199/14182
- MTS-GCO-98-913NE
- ALLERGAN-MTS-GCO-98-913NE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperhidrosis
-
Dryox HealthTerminatedPalmar HyperhidrosisSpain
-
Atacama TherapeuticsCompletedPalmar HyperhidrosisUnited States
-
Miramar LabsCompletedAxillary HyperhidrosisCanada
-
Commons Aesthetic Plastic SurgerySound Surgical Technologies, LLC.CompletedAxillary HyperhidrosisUnited States
-
Tishreen UniversityRecruiting
-
Botanix PharmaceuticalsCompletedPrimary Axillary HyperhidrosisUnited States
-
Dr. August Wolff GmbH & Co. KG ArzneimittelFGK Clinical Research GmbH; Nuvisan GmbH; Charles River Biopharmaceutical Services...CompletedPrimary Axillary HyperhidrosisGermany
-
Ulthera, IncTerminatedPrimary Axillary HyperhidrosisUnited States
-
Mae Fah Luang University HospitalCompletedPrimary Axillary Hyperhidrosis
-
Grupo de Cirurgia VascularCompleted
Clinical Trials on botulinum toxin type A
-
AllerganTerminatedOveractive BladderSerbia, Turkey, Greece, Egypt, Lebanon, India
-
Daewoong Pharmaceutical Co. LTD.Completed
-
AllerganCompletedOveractive BladderPortugal, South Africa, Netherlands, Canada, Singapore, Brazil, United States, Taiwan, Italy, United Kingdom, France, Spain
-
AllerganCompletedOveractive BladderUnited Kingdom, Belgium, New Zealand, France, Russian Federation, Czech Republic, United States, Germany, Austria, Poland, Slovakia, Ukraine, Canada, Australia
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar RhytidesUnited States
-
Brazilan Center for Studies in DermatologyCompletedWrinkles in Frontal AreaBrazil
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar Rhytides | Frown Lines Between the EyebrowsUnited States
-
HugelCompletedBenign Masseteric HypertrophyKorea, Republic of
-
Medy-ToxCompletedCervical Dystonia
-
INIBIO Co., Ltd.Completed